Title:
SUBSTITUTED 2-MORPHOLINOPYRIDINE DERIVATIVES AS ATR KINASE INHIBITORS
Document Type and Number:
WIPO Patent Application WO/2021/012049
Kind Code:
A8
Abstract:
Disclosed are compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein — is a single bond, and each Y is N or CR4; or — is absent, and each Y is NRY, carbonyl, or C(RY)2, wherein each R1 is H or optionally substituted C1-6 alkyl; R1 is optionally substituted C1-6 alkyl or H; R3 is optionally substituted C1-9 heteroaryl or optionally substituted C1-9 heteroarylC1-6 alkyl; each R4 is hydrogen, halogen, optionally substituted C1-6 alkyl, optionally substituted C2-6 alkenyl, or optionally substituted C2-6 alkynyl; X is hydrogen or halogen; and R2 is as defined in claim 1. Also disclosed are pharmaceutical compositions containing the compounds of formula (I) and methods for their preparation. The compounds of formula (I) may be inhibitors of Ataxia-telangiectasia and RAD-3 -related protein kinase (ATR) and used for the treatment of diseases or conditions such as cancers.
More Like This:
Inventors:
CRANE SHELDON N (CA)
TRUONG VOUY LINH (CA)
ABDOLI ABBAS (CA)
TRUCHON JEAN-FRANÇOIS (CA)
BLACK CAMERON (CA)
DORICH STÉPHANE (CA)
FADER LEE (CA)
LANOIX STÉPHANIE (CA)
JONES PAUL (CA)
ST-ONGE MIGUEL (CA)
PICARD AUDREY (CA)
LACBAY CYRUS M (CA)
TRUONG VOUY LINH (CA)
ABDOLI ABBAS (CA)
TRUCHON JEAN-FRANÇOIS (CA)
BLACK CAMERON (CA)
DORICH STÉPHANE (CA)
FADER LEE (CA)
LANOIX STÉPHANIE (CA)
JONES PAUL (CA)
ST-ONGE MIGUEL (CA)
PICARD AUDREY (CA)
LACBAY CYRUS M (CA)
Application Number:
PCT/CA2020/051014
Publication Date:
April 15, 2021
Filing Date:
July 22, 2020
Export Citation:
Assignee:
REPARE THERAPEUTICS INC (CA)
International Classes:
C07D471/04; A61K31/5377; A61P35/00
Attorney, Agent or Firm:
NAUMAN, David et al. (CA)
Download PDF: